On the evening of June 23rd, the CSIMIT Cloud Academy, supported by Alpmed and hosted by the Minimally Invasive Treatment Professional Committee of the Chinese Medical Education Association, successfully concluded its project on the interpretation of expert consensus on image-guided irreversible electroporation ablation therapy for liver cancer. The conference adopted a combination of online and offline methods, with a branch venue set up in Xi'an, attracting over 2,000 doctors to watch online simultaneously!

Professor Xiaoyue Yong from the First Medical Center of the Beijing PLA General Hospital was invited to serve as the chairman of the conference. Professor Zhongmin Wang from the Department of Radiology and Interventional Medicine at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine and Professor Yingtian Wei from the Department of Radiology and Interventional Medicine at the First Medical Center of the Beijing PLA General Hospital were invited as keynote speakers. At the same time, Professor Lijun Sun from the Department of Interventional Medicine at the Air Force Medical University was invited to serve as the chairman of the branch venue in Xi'an. Professor Xiaoyue Yong delivered a professional and rigorous opening speech. He stated that this was a great opportunity for learning and communication. As a new method for tumor treatment, he hoped that all parties could work together to quickly enable more doctors to understand and master this technology, ultimately bringing good news to patients with malignant liver tumors.

Excerpt from Director Xiao Yueyong

Professor Sun Lijun from the Xi'an offline branch venue delivered a speech, expressing that the course content arrangement of this conference is highly anticipated and will contribute to the better standardization of NanoKnife treatment in the future. He also hopes that through this joint learning, clinical doctors at all levels can further strengthen their understanding of NanoKnife technology.

Subsequently, Jiao Junhan, General Manager of Shanghai Yuanshan Medical Technology Co., Ltd.(Alpmed), spoke on behalf of the company. He stated that after 8 years of overcoming difficulties and deep cultivation in the irreversible electroporation technology field, Alpmed successfully obtained the first domestic registration certificate for Class III medical devices in the field of irreversible electroporation applied to malignant liver tumors in 2021.Up to now, Alpmed has carried out NanoKnife surgery in more than 25 hospitals in over 10 provinces in China. He expressed gratitude to the many domestic experts and scholars who have supported Alpmed's NanoKnife products along the way. In the future,Alpmed will continue to move forward with the original intention of innovation and strive to benefit more patients with high-quality domestic medical device products.

As the keynote speaker, Professor Wang Zhongmin started from classic cases and used practical treatment cases of tumors located in special positions to illustrate the advantages and technical points of irreversible electroporation technology. Combining with the surgical process, Professor Wang pointed out that before carrying out NanoKnife ablation treatment, it is necessary to accurately evaluate the location of the tumor as much as possible in order to better plan the needle insertion path. Finally, Professor Wang stated that NanoKnife treatment for tumors in special locations is relatively safer and more effective than radiofrequency treatment. The damage to large blood vessels in the tumor ablation area is smaller and the ablation boundary is clearer, making it a very good technology. He believes that NanoKnife will have a very promising future, and hopes that domestic NanoKnife products can work with them to carry out more cutting-edge research.

Professor Wei Yingtian shared the 2022 expert consensus on image-guided irreversible electroporation ablation therapy for liver cancer, and explained in detail the precautions for treating tumors in special locations with NanoKnife, as well as the five areas where NanoKnife is most suitable for application in the liver field. She also discussed the anesthesia methods and precautions during NanoKnife treatment.

During the discussion session of the conference, the audience responded enthusiastically, and the Xi'an offline sub-venue frequently asked questions. The three experts jointly answered the questions raised by the sub-venue colleagues and online viewers. One teacher asked about the indications for domestic NanoKnife, which happens to be a clinical project of the "Domestic NanoKnife" - High Voltage Steep Pulse Minimally Invasive Therapeutic System. It has already conducted clinical trials for pancreatic cancer in tertiary hospitals in many provinces across the country, and will also conduct clinical trials in other fields in the future. In this session, the experts also discussed related issues such as how to design parameters for "Domestic NanoKnife" treatment, whether patients can still undergo NanoKnife treatment if they have metal biliary stents, the application of NanoKnife in lung tumors, and the advantages and differences compared with microwave treatment. It is believed that through the answers of the experts and the joint communication of online and offline, the attending doctors have a clearer understanding and expectation of the prospects of irreversible electroporation technology in clinical application.

The clinical trial project of "domestic NanoKnife" for ablation treatment of pancreatic cancer is being carried out in tertiary hospitals in multiple provinces across the country, and volunteer recruitment is currently underway. If you have any questions, you can leave a message in the background for consultation, and the staff will help you answer relevant questions as soon as possible.